Insights into receptor function and new drug development targets

Conn, M. / Kordon, C. / Christen, Y. (eds.):

ISBN 10: 3540344462 / ISBN 13: 9783540344469

Published by Berlin u. a., Springer, 2006., 2006

About this Item

8°, Original hardcover with XV, 202 pages, color illustrations. In good condition. -- Original-Pappband mit XV, 202 Seiten, farbig bebildert. Sauberer, guter Zustand. -- Bitte Portokosten außerhalb EU erfragen! / Please ask for postage costs outside EU! / S ' il vous plait demander des frais de port en dehors de l ' UE! // Bitte beachten Sie auch unsere Fotos! / Please also note our photos! / Veuillez noter nos photos -- Gönnen Sie sich ein interessantes Buch zum Tee! Bei uns werden Sie fündig. -- Wir kaufen Ihre werthaltigen Bücher! Biol.

Seller Inventory # 437360

Bibliographic Details

• Title: Insights into receptor function and new drug development targets
• Publisher: Berlin u. a., Springer, 2006.
• Publication Date: 2006
• Language: English
• ISBN 10: 3540344462
• ISBN 13: 9783540344469
• Binding: Hardcover
• Edition: 1st Edition
• Seller catalogs:
  • Biologie

About this title

Synopsis

We are now on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The recognition, for example, that mutant proteins are frequently misrouted molecules, rather than functionally defective ones, changes our approach to "inborn errors of metabolism" and offers new approaches for pharmacological discovery, based on rescue of receptors, ion channels and enzymes with pharmacoperones. Ion channels, regulators of G-protein signaling and enzymes engaged in regulation, now present opportunities for drug development.

The state of our art also benefits by the availability of superior tools that allow measurement of interactions and afford unprecedented insight into the biomolecular interactions that present novel approaches to drug design.

From the Back Cover

G-Protein Coupled receptors (GPCRs) and other receptors are significant targets for drug discovery, due to their roles in fundamental physiological processes. Among these roles are: regulation of growth, food intake, reproduction, water balance, sensory perception, blood pressure and heart rate. GPCR-directed drugs account for approximately $40 billion in sales and, of drugs at market, approximately 70% target GPCR function.

The availability of combinatorial chemistry coupled with high throughput screening techniques have facilitated discovery of peptidic and non-peptidic ligands of membrane receptors. Mutant receptor models have revealed their role in health and disease and provided insight to new therapeutic approaches, based on control of protein trafficking. Understanding receptor-receptor interactions has provided one mechanism for receptor cross-talk and revealed unexpected interactions.

The completion of the human genome has identified a new source of therapeutic targets: "orphan receptors" with unknown functions and yet-to-be discovered ligands. Some orphans have now been identified as ghrelin, nociceptin, apelin, and urocortin. This finding, along with important technologies to develop ligands with desirable characteristics, including peptidomimetics is likely to further accelerate interest in this area.